An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis

NCT03758716 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: FB825, FB825-15D11, Anti-CemX

Sponsor

Fountain Biopharma Inc.